AI Engines For more Details: Perplexity Kagi Labs You
Digestive Disorders: Some individuals with digestive disorders such as irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD) may be sensitive to certain food additives, including SSL. While SSL is not typically associated with gastrointestinal symptoms, some individuals with digestive disorders may experience discomfort or exacerbation of symptoms after consuming foods containing SSL.
Food Allergies and Sensitivities: Individuals with food allergies or sensitivities may react to certain food additives, including SSL. While SSL itself is not a common allergen, it may be derived from ingredients such as milk or soy, which are common allergens. Individuals with known allergies or sensitivities to milk or soy should exercise caution when consuming foods containing SSL and carefully read food labels.
Cardiovascular Health: SSL is derived from stearic acid, a type of saturated fatty acid found in various food sources. While moderate consumption of saturated fats is generally considered acceptable, excessive intake of saturated fats may contribute to elevated cholesterol levels and increase the risk of cardiovascular diseases such as heart disease and stroke. However, the contribution of SSL specifically to cardiovascular health is not well-studied.
Metabolic Disorders: Some research suggests that certain food additives, including SSL, may have potential impacts on metabolic health, including glucose metabolism and insulin sensitivity. However, the specific effects of SSL on metabolic disorders such as diabetes or metabolic syndrome are not well-established and require further research.
Inflammatory Conditions: SSL is generally considered safe for consumption and is not typically associated with inflammatory conditions. However, individuals with conditions characterized by chronic inflammation, such as rheumatoid arthritis or inflammatory bowel disease, may benefit from minimizing their intake of processed foods containing additives like SSL.
Rank | Probiotic | Impact |
---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.8 | -0.8 | |
Acne | 0.3 | 1.8 | -5 |
ADHD | 2.8 | 4.6 | -0.64 |
Age-Related Macular Degeneration and Glaucoma | 0.6 | 1 | -0.67 |
Allergic Rhinitis (Hay Fever) | 1.7 | 2.8 | -0.65 |
Allergies | 6.9 | 7.5 | -0.09 |
Allergy to milk products | 5.3 | 2.2 | 1.41 |
Alopecia (Hair Loss) | 2.4 | 0.3 | 7 |
Alzheimer's disease | 7.3 | 10.9 | -0.49 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 4.8 | 2.9 | 0.66 |
Ankylosing spondylitis | 4.8 | 4.7 | 0.02 |
Anorexia Nervosa | 2.6 | 5.4 | -1.08 |
Antiphospholipid syndrome (APS) | 0.2 | -0.2 | |
Asthma | 4.4 | 6.2 | -0.41 |
Atherosclerosis | 0.8 | 2.5 | -2.13 |
Atrial fibrillation | 4.5 | 3.8 | 0.18 |
Autism | 9.6 | 9.2 | 0.04 |
Autoimmune Disease | 0.1 | 2.7 | -26 |
benign prostatic hyperplasia | 0.5 | 2.1 | -3.2 |
Biofilm | 0.2 | -0.2 | |
Bipolar Disorder | 4.5 | 5.2 | -0.16 |
Brain Trauma | 2.4 | 1.7 | 0.41 |
Breast Cancer | 1.2 | 0.3 | 3 |
Cancer (General) | 0.3 | 0.6 | -1 |
Carcinoma | 2.6 | 3.5 | -0.35 |
Celiac Disease | 3 | 5.9 | -0.97 |
Cerebral Palsy | 1.7 | 2.9 | -0.71 |
Chronic Fatigue Syndrome | 3.9 | 4.6 | -0.18 |
Chronic Kidney Disease | 1.5 | 5.2 | -2.47 |
Chronic Lyme | 0.5 | 0.9 | -0.8 |
Chronic Obstructive Pulmonary Disease (COPD) | 4.5 | 2.4 | 0.88 |
Chronic Urticaria (Hives) | 1.1 | 1.8 | -0.64 |
Coagulation / Micro clot triggering bacteria | 0.5 | 4.1 | -7.2 |
Cognitive Function | 3.5 | 3.1 | 0.13 |
Colorectal Cancer | 6.6 | 6.2 | 0.06 |
Constipation | 2.4 | 4.3 | -0.79 |
Coronary artery disease | 3.5 | 5.6 | -0.6 |
COVID-19 | 5.3 | 11.3 | -1.13 |
Crohn's Disease | 7.2 | 11.1 | -0.54 |
Cushing's Syndrome (hypercortisolism) | 0.5 | 0.5 | |
cystic fibrosis | 0.5 | 3 | -5 |
d-lactic acidosis (one form of brain fog) | 0.2 | -0.2 | |
deep vein thrombosis | 1.4 | 2.8 | -1 |
Denture Wearers Oral Shifts | 0.3 | 0.3 | |
Depression | 11.1 | 11.7 | -0.05 |
Dermatomyositis | 1.5 | 0.5 | 2 |
Eczema | 1.5 | 3.3 | -1.2 |
Endometriosis | 2.7 | 3.8 | -0.41 |
Eosinophilic Esophagitis | 1.4 | -1.4 | |
Epilepsy | 4.2 | 4.6 | -0.1 |
erectile dysfunction | 1.5 | 2.3 | -0.53 |
Fibromyalgia | 2.9 | 2 | 0.45 |
Functional constipation / chronic idiopathic constipation | 7.4 | 7.5 | -0.01 |
gallstone disease (gsd) | 2.9 | 1.4 | 1.07 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.2 | 2.1 | -0.75 |
Generalized anxiety disorder | 3.4 | 3.5 | -0.03 |
giant cell arteritis | 0.5 | 0.7 | -0.4 |
Glioblastoma | 0.6 | 1.9 | -2.17 |
Gout | 1.8 | 4.7 | -1.61 |
Graves' disease | 2.2 | 5 | -1.27 |
Gulf War Syndrome | 1.8 | 1.1 | 0.64 |
Halitosis | 2.1 | -2.1 | |
Hashimoto's thyroiditis | 4.4 | 2.3 | 0.91 |
Heart Failure | 3.1 | 5.2 | -0.68 |
hemorrhagic stroke | 1.4 | 0.5 | 1.8 |
Hemorrhoidal disease, Hemorrhoids, Piles | 0.3 | 0.3 | |
Hidradenitis Suppurativa | 0.1 | 1.9 | -18 |
High Histamine/low DAO | 1.1 | 1.8 | -0.64 |
hypercholesterolemia (High Cholesterol) | 0.5 | 1.1 | -1.2 |
hyperglycemia | 1.5 | 1.4 | 0.07 |
Hyperlipidemia (High Blood Fats) | 0.2 | 1.1 | -4.5 |
hypersomnia | 0.1 | 1.8 | -17 |
hypertension (High Blood Pressure | 5.1 | 7.2 | -0.41 |
Hypothyroidism | 1.6 | 4.3 | -1.69 |
Hypoxia | 2.3 | 1.8 | 0.28 |
IgA nephropathy (IgAN) | 2.8 | 4 | -0.43 |
Inflammatory Bowel Disease | 5.2 | 8.7 | -0.67 |
Insomnia | 4.6 | 4.3 | 0.07 |
Intelligence | 3.8 | 1 | 2.8 |
Intracranial aneurysms | 2.5 | 2.3 | 0.09 |
Irritable Bowel Syndrome | 7.8 | 9 | -0.15 |
ischemic stroke | 4.8 | 5.6 | -0.17 |
Juvenile idiopathic arthritis | 0.3 | -0.3 | |
Liver Cirrhosis | 5.7 | 5.8 | -0.02 |
Long COVID | 8.9 | 11 | -0.24 |
Low bone mineral density | 0.5 | 2.1 | -3.2 |
Lung Cancer | 0.5 | 3.4 | -5.8 |
Lymphoma | 1.3 | -1.3 | |
Mast Cell Issues / mastitis | 1.5 | 2.2 | -0.47 |
ME/CFS with IBS | 1.2 | 0.5 | 1.4 |
ME/CFS without IBS | 1.7 | 0.3 | 4.67 |
membranous nephropathy | 0.6 | -0.6 | |
Menopause | 1.4 | -1.4 | |
Metabolic Syndrome | 7.1 | 11.1 | -0.56 |
Mood Disorders | 12.4 | 11.4 | 0.09 |
multiple chemical sensitivity [MCS] | 0.4 | -0.4 | |
Multiple Sclerosis | 5.1 | 6 | -0.18 |
Multiple system atrophy (MSA) | 0.7 | -0.7 | |
myasthenia gravis | 1.9 | 2.6 | -0.37 |
neuropathic pain | 0.5 | 0.9 | -0.8 |
Neuropathy (all types) | 1.6 | 1.4 | 0.14 |
neuropsychiatric disorders (PANDAS, PANS) | 2.4 | -2.4 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5.8 | 9 | -0.55 |
NonCeliac Gluten Sensitivity | 1.7 | 1.3 | 0.31 |
Obesity | 9.5 | 11.3 | -0.19 |
obsessive-compulsive disorder | 2.3 | 5.3 | -1.3 |
Osteoarthritis | 1.8 | 2.9 | -0.61 |
Osteoporosis | 2.5 | 4.4 | -0.76 |
pancreatic cancer | 0.6 | 2.1 | -2.5 |
Parkinson's Disease | 6.9 | 10.8 | -0.57 |
Peanut Allergy | 0.5 | -0.5 | |
Polycystic ovary syndrome | 6.9 | 8.4 | -0.22 |
Postural orthostatic tachycardia syndrome | 0.7 | 0.9 | -0.29 |
Premenstrual dysphoric disorder | 0.7 | 0.3 | 1.33 |
primary biliary cholangitis | 0.8 | 2.6 | -2.25 |
Primary sclerosing cholangitis | 1.7 | 3.9 | -1.29 |
Psoriasis | 3 | 1.6 | 0.88 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 7.6 | 7.8 | -0.03 |
Rosacea | 0.4 | 1.5 | -2.75 |
Schizophrenia | 7.2 | 7.7 | -0.07 |
scoliosis | 1.9 | 0.3 | 5.33 |
sensorineural hearing loss | 0.5 | -0.5 | |
Sjögren syndrome | 2.4 | 4.3 | -0.79 |
Sleep Apnea | 3.3 | 3.2 | 0.03 |
Slow gastric motility / Gastroparesis | 0.9 | 1.1 | -0.22 |
Small Intestinal Bacterial Overgrowth (SIBO) | 2 | 2.7 | -0.35 |
Stress / posttraumatic stress disorder | 1.9 | 4.8 | -1.53 |
Systemic Lupus Erythematosus | 3.3 | 8.5 | -1.58 |
Tic Disorder | 2.3 | 0.9 | 1.56 |
Tourette syndrome | 0.8 | 0.5 | 0.6 |
Type 1 Diabetes | 5 | 5.9 | -0.18 |
Type 2 Diabetes | 7.4 | 9.5 | -0.28 |
Ulcerative colitis | 9 | 7.9 | 0.14 |
Unhealthy Ageing | 1.9 | 3 | -0.58 |
Vitiligo | 1.2 | 1.2 | 0 |